Physician profile
Catherine E Makin
NPI 1932469251
$6,238.18
in general payments reported to CMS, 2019-2025
21 companies · $1,484 in 2025
The $1,484 reported for 2025 was more than what 85% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $158 · 2021: $767 · 2022: $789 · 2023: $1,737 · 2024: $1,304 · 2025: $1,484.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,490 · Travel and Lodging: $992 · Gift: $43.28.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,489.73 |
| Travel and Lodging | $992.07 |
| Gift | $43.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $2,412.63 | 2021-2025 | |
| Abbvie INC. | $1,269.88 | 2023-2025 | |
| Rxsight INC | $541.36 | 2021-2025 | Rxsight Contact Lens, Rxsight Injector Cartridge, Light Adjustable Lens (Lal) |
| Alcon Vision LLC | $384.59 | 2020-2025 | Hydrus Microstent, Clareon, Simbrinza |
| Johnson & Johnson Surgical Vision, INC. | $197.83 | 2020-2022 | |
| Horizon Therapeutics Plc | $196.78 | 2020-2023 | Tepezza |
| Novartis Pharmaceuticals Corporation | $184.41 | 2021-2023 | |
| Sun Pharmaceutical Industries INC. | $181.77 | 2020-2023 | Cequa, Xelpros |
| Allergan, INC. | $146.94 | 2020-2021 | |
| Bausch & Lomb Americas INC. | $146.82 | 2022-2024 | Vyzulta, Miebo |
| Regeneron Pharmaceuticals, INC. | $130.02 | 2023 | Eylea |
| Dompe US, INC. | $99.96 | 2021-2025 | Oxervate |
| Amgen INC. | $96.94 | 2024-2025 | Tepezza |
| Sight Sciences, INC. | $96.30 | 2022-2025 | Omni Surgical System, Sion Surgical Instrument |
| Ocular Therapeutix, INC. | $43.96 | 2022-2023 | Dextenza |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $23.44 | 2024 | Izervay |
| Omeros Corporation | $19.24 | 2021 | |
| Tarsus Pharmaceuticals, INC. | $18.88 | 2024 | Xdemvy |
| Thea Pharma INC. | $18.86 | 2025 | Iyuzeh |
| Tearlab Corp | $16.11 | 2023 | Tearlab Osmolarity System |
| Kala Pharmaceuticals, INC. | $11.46 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Makin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.